About Katie

Katie Lapidus advises private and public companies of all stages on a variety of corporate matters including formation, financing activities, corporate governance and securities law compliance. Katie also represents companies and underwriters in initial public offerings and follow-on securities offerings and counsels public companies with respect to SEC reporting obligations.

View full bio

Passions

True Crime

Peloton

Experience

Alto Neuroscience – $75 Million Debt Financing

Alto Neuroscience – $75 Million Debt Financing

January 13, 2025

Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its up to $75 million debt financing. Partner Addison Pierce led the Cooley team, which included Courtney Tygesson, Madison Jones, Margaret Barreto and Katie Lapidus.

Related contacts

Addison Pierce
Partner, Chicago
Courtney M.W. Tygesson
Partner, Chicago
Madison Jones
Partner, Washington, DC
Margaret Barreto
Associate, San Francisco
Katie Lapidus
Associate, Washington, DC

Alto Neuroscience Announces $147.9 Million IPO

Alto Neuroscience Announces $147.9 Million IPO

February 6, 2024

Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its $147.9 million initial public offering.

Read more

Related contacts

Div Gupta
Partner, New York
Christina T. Roupas
Partner in Charge – Chicago, Chicago
Courtney M.W. Tygesson
Partner, Chicago
Laurie Bauer
Partner, Chicago
Nyron J. Persaud
Partner, New York
Dr. Jon Cousin
Partner, Washington, DC
Eileen Marshall
Partner, Washington, DC
Geoffrey Spolyar
Partner, Boston
Stephanie Gentile
Partner, New York
Steve Flores
Partner, Chicago
Peter Adams
Partner, San Diego
Phil Mitchell
Partner, New York
Courtney Thorne
Partner, London
Francis Wheeler
Senior Counsel, Colorado
Natasha Leskovsek
Of Counsel, Washington, DC
Rebecca Ross
Special Counsel, Washington, DC
Randy Sabett
Special Counsel, Washington, DC
Dani Nazemian
Special Counsel, San Diego
Katie Lapidus
Associate, Washington, DC
Trey Reilly
Associate, New York
Adam Bloom
Associate, Chicago
Megan E. Bowles
Associate, Chicago
Edmond Lay
Partner, San Diego
Addison Pierce
Partner, Chicago
Calvin Lee
Associate, New York
Andrew Nelms
Associate, San Francisco
Jason Minio
Paralegal Specialist, Boston
Jeffery Wyzykowski
Patent Agent, Washington, DC

Related Practices & Industries

Capital Markets
Life Sciences
Life Sciences and Healthcare Regulatory
Life Sciences Corporate Partnering and Licensing
Healthcare
Patent Counseling and Prosecution
Emerging Companies
Compensation and Benefits
Labor and Employment
Cyber/Data/Privacy
Debt Finance
CFIUS
Tax

Cara Therapeutics, Inc. -- $40 Million Royalty Interest Purchase and Sale Agreement

Cara Therapeutics, Inc. -- $40 Million Royalty Interest Purchase and Sale Agreement

November 3, 2023

Cooley advised Cara Therapeutics, Inc. on its $40 million royalty interest purchase and sale agreement with HealthCare Royalty Partners. Michael Tollini and Addison Pierce led the Cooley team advising Cara, which included Bin Wang, Xueqing Li and Jordan Verrilli. Cara, which trades on The NASDAQ Global Market as “CARA,” is a clinical-stage biotech company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors.

Related contacts

Michael Tollini
Partner, Washington, DC
Addison Pierce
Partner, Chicago
Bin Wang
Special Counsel, Palo Alto
Xueqing Li
Associate, San Francisco
Katherine Denby
Special Counsel, Washington, DC
Darren DeStefano
Partner, Reston
Katie Lapidus
Associate, Washington, DC
Steve Flores
Partner, Chicago
Xander Lee
Partner, Santa Monica
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York
Francis Wheeler
Senior Counsel, Colorado

Related Practices & Industries

Debt Finance
Life Sciences

Immunology Company argenx Announces $1.27 Billion Global Offering

Immunology Company argenx Announces $1.27 Billion Global Offering

July 26, 2023

Cooley advised J.P. Morgan, Morgan Stanley, Goldman Sachs, BofA Securities and TD Cowen, representatives of the several underwriters, in the $1.27 billion follow-on offering by argenx SE, a global immunology company.

Read more

Related contacts

Richard Segal
Partner, New York
Div Gupta
Partner, New York
Darah Protas
Partner, Washington, DC
Katie Lapidus
Associate, Washington, DC
Phil Mitchell
Partner, New York
Natasha Leskovsek
Of Counsel, Washington, DC

Related Practices & Industries

Capital Markets
Life Sciences
Intellectual Property
Healthcare

NewAmsterdam Pharma – $181.6 Million Follow-on Offering

NewAmsterdam Pharma – $181.6 Million Follow-on Offering

June 6, 2023

Cooley advised the underwriters in NewAmsterdam Pharma’s $181.6 million follow-on offering. NewAmsterdam is a clinical-stage biopharmaceutical company with a mission to improve care of patients with metabolic diseases where currently approved therapies have not been sufficiently successful or well tolerated. Lawyers Eric Blanchard, Div Gupta, Jean Park, Minkyu Park, Charles York, and Katie Lapidus led the Cooley team.

Related contacts

Eric Blanchard
Partner, Boston
Div Gupta
Partner, New York
Jean Park
Partner, New York
Minkyu Park
Special Counsel, New York
Katie Lapidus
Associate, Washington, DC

Related Practices & Industries

Capital Markets
Life Sciences
View more

Admissions and credentials

District of Columbia

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.